Arcellx Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Arcellx şirketinin toplam hissedar öz sermayesi $487.2M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $734.3M ve $247.1M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$516.69m
Eşitlik	US$487.16m
Toplam yükümlülükler	US$247.14m
Toplam varlıklar	US$734.31m

Son finansal sağlık güncellemeleri

Recent updates

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Oct 28

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

Sep 10

There's Reason For Concern Over Arcellx, Inc.'s (NASDAQ:ACLX) Massive 28% Price Jump

Sep 05

We're Interested To See How Arcellx (NASDAQ:ACLX) Uses Its Cash Hoard To Grow

Aug 10

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Jul 12

News Flash: Analysts Just Made A Sizeable Upgrade To Their Arcellx, Inc. (NASDAQ:ACLX) Forecasts

Jun 01

Rainbows and Unicorns: Arcellx, Inc. (NASDAQ:ACLX) Analysts Just Became A Lot More Optimistic

May 14

Is Arcellx (NASDAQ:ACLX) A Risky Investment?

May 12

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 01

Arcellx: Navigating The CAR T-Cell Revolution

Jan 30

Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues

Nov 18

Earnings Miss: Arcellx, Inc. Missed EPS And Analysts Are Revising Their Forecasts

May 10

Companies Like Arcellx (NASDAQ:ACLX) Are In A Position To Invest In Growth

Nov 17

Arcellx: The Best Is Yet To Come

Aug 23

Arcellx GAAP EPS of -$0.88

Aug 15

Arcellx down 9% on day lock-up period ends

Aug 03

We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely

Jun 27

Arcellx: Speculative Buy For Their 'Best-In-Class' CAR-T Cell Therapy

Jun 08

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ACLX 'nin kısa vadeli varlıkları ( $530.2M ) kısa vadeli yükümlülüklerini ( $88.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: ACLX şirketinin kısa vadeli varlıkları ( $530.2M ) uzun vadeli yükümlülüklerini ( $158.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ACLX borçsuzdur.

Borcun Azaltılması: ACLX son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ACLX şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: ACLX tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Arcellx Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're Interested To See How Arcellx (NASDAQ:ACLX) Uses Its Cash Hoard To Grow

Is Arcellx (NASDAQ:ACLX) A Risky Investment?

Companies Like Arcellx (NASDAQ:ACLX) Are In A Position To Invest In Growth

Arcellx, Inc. announced delayed 10-Q filing

We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely

Recent updates

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Independent Director notifies of intention to sell stock

Price target increased by 7.1% to US$89.67

Now 20% overvalued after recent price rise

Chief Financial Officer notifies of intention to sell stock

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

There's Reason For Concern Over Arcellx, Inc.'s (NASDAQ:ACLX) Massive 28% Price Jump

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$320k worth of stock

Consensus revenue estimates increase by 21%

We're Interested To See How Arcellx (NASDAQ:ACLX) Uses Its Cash Hoard To Grow

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Now 21% undervalued after recent price drop

Chief Medical Officer exercised options and sold US$990k worth of stock

Now 21% overvalued after recent price rise

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Now 21% undervalued after recent price drop

New major risk - Revenue and earnings growth

News Flash: Analysts Just Made A Sizeable Upgrade To Their Arcellx, Inc. (NASDAQ:ACLX) Forecasts

Consensus revenue estimates increase by 14%

Chief Financial Officer notifies of intention to sell stock

Consensus revenue estimates increase by 11%

Rainbows and Unicorns: Arcellx, Inc. (NASDAQ:ACLX) Analysts Just Became A Lot More Optimistic

Is Arcellx (NASDAQ:ACLX) A Risky Investment?

New major risk - Revenue and earnings growth

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Chief Medical Officer exercised options and sold US$818k worth of stock

Arcellx, Inc., Annual General Meeting, May 24, 2024

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 10%

Price target increased by 13% to US$75.92

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 10.0% to US$72.27

Chairman of the Board recently sold US$2.4m worth of stock

New major risk - Revenue and earnings growth

Chairman of the Board notifies of intention to sell stock

Arcellx: Navigating The CAR T-Cell Revolution

Chairman of the Board recently sold US$1.6m worth of stock

Chairman of the Board notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Price target increased by 8.5% to US$65.18

Arcellx, Inc. Announces Continued Robust Long-Term Responses from its Cart-Ddbcma Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma At Ash

Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues

Arcellx, Inc. announced that it expects to receive $199.999991 million in funding from Gilead Sciences, Inc.

Price target increased by 9.5% to US$56.55

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 11%

Arcellx, Inc. Announces Oral Presentation for CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma At the 65th ASH Annual Meeting and Exposition

Consensus revenue estimates fall by 47%

Arcellx, Inc. Announces Partial Clinical Hold Lifted on Immagine-1 Phase 2 Clinical Program

Arcellx, Inc. Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program

Chairman of the Board recently sold US$115k worth of stock

Consensus EPS estimates fall by 365%

Price target increased by 12% to US$47.56

Earnings Miss: Arcellx, Inc. Missed EPS And Analysts Are Revising Their Forecasts

Price target increased by 9.2% to US$43.56

Chief Medical Officer notifies of intention to sell stock

Price target increased by 7.9% to US$42.33

Chief Medical Officer exercised options and sold US$404k worth of stock

Chief Medical Officer notifies of intention to sell stock

Arcellx, Inc. announced that it has received $100.000004 million in funding from Gilead Sciences, Inc.

Insider recently sold US$51k worth of stock

Insider recently sold US$51k worth of stock

Chief Medical Officer exercised options and sold US$231k worth of stock

Arcellx, Inc. Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress

Companies Like Arcellx (NASDAQ:ACLX) Are In A Position To Invest In Growth

High number of new directors